The UC Davis Cancer Center Animal Imaging (CCAl) Shared Resource addresses the growing importance of anatomic, functional and molecular imaging in cancer research by providing Cancer Center researchers access to state-of-the-art imaging equipment, novel targeted imaging tracers, experienced technical support personnel and support for data acquisition and analysis. The CCAl shared resource includes an unparalleled array of small and large animal (clinical) imaging technologies for minimally invasive and non-destructive morphologic and physiologic imaging. The resource is comprised of two inter-related facilities within the Department of Biomedical Engineering and the School of Veterinary Medicine Teaching Hospital that house a microPET, a cyclotron and radiopharmacy, gamma camera, small animal and large animal helical CT, clinical (1.5T) and high-field (7.0T) MRI, optical (bioluminescence) imaging, ultra-high frequency and clinical ultrasound, high-resolution low-energy radiography, clinical radiography and fluoroscopy, anesthesia and monitoring equipment and animal housing for both small and large animals. The objectives of the CCAl shared resource are: 1) Provide Cancer Center members direct access to a comprehensive, multimodality research imaging resource for studies involving induced cancer models in small animals (primarily mice and rats) 2) Provide Cancer Center members direct access to a comprehensive, multimodality research imaging resource for studies involving spontaneous and induced cancer models in large animals (dog, cat, pig, etc). 3) Design and synthesize novel imaging tracers for studies involving targeted tracer delivery. 4) Provide professional consultation to investigators for design of experimental studies. 5) Provide technical support to CC members for execution of animal imaging studies and for collection and analysis of data.
The UC Davis Cancer Center Animal Imaging (CCAl) Shared Resource facilitates cancer-related research involving small and large animal imaging thereby reducing costs, increasing efficiency and improving the productivity of Cancer Center researchers through thoughtful design, execution and analysis of imaging studies.
|Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24|
|Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24|
|Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4|
|Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9|
|Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6|
|Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25|
|Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8|
|Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49|
|Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40|
|Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6|
Showing the most recent 10 out of 84 publications